Patents by Inventor Haixia Wang

Haixia Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
    Patent number: 8546394
    Abstract: Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d).
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: October 1, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jun Li, James J. Li, Stephen P. O'Connor, Haixia Wang, Lawrence J. Kennedy, Jeffrey A. Robl, Lawrence G. Hamann
  • Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 8541444
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: September 24, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jun Li, Jeffrey A. Robl, James J. Li, Lawrence J. Kennedy, Haixia Wang, Jie Jack Li, Chenkou Wei, Michael Galella
  • Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 8158648
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z??(I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L and Z are defined herein.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: April 17, 2012
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang
  • Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 8148396
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R3, R3a, R3b and R4 are defined herein.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robl
  • Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 8119658
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: February 21, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jun Li, Jeffrey A. Robl, James J. Li, Lawrence J. Kennedy, Haixia Wang, Jie Jack Li, Xinhua Qian, Rajendra P. Deshpande, Laxma R. Kolla, Reginald O. Cann, Chenkou Wei, Michael Galella
  • TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
    Publication number: 20110288051
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.
    Type: Application
    Filed: August 3, 2011
    Publication date: November 24, 2011
    Inventors: Jun Li, Jeffrey A. Robl, James J. Li, Lawrence J. Kennedy, Haixia Wang, Jie Jack Li, Chenkou Wei, Michael Galella
  • Modulators of LXR
    Patent number: 8013001
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: September 6, 2011
    Assignee: Exelixis, Inc.
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, Jr., Haixia Wang, Yinong Xie
  • INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I
    Publication number: 20110077395
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R6, R7, and R8 are defined herein.
    Type: Application
    Filed: December 2, 2010
    Publication date: March 31, 2011
    Inventors: James J. Li, Lawrence G. Hamann, Zheming Ruan, Christopher B. Cooper, Shung C. Wu, Ligaya M. Simpkins, Haixia Wang, Akbar Nayeem, Stanley R. Krystek
  • PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS
    Publication number: 20100216791
    Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: August 15, 2007
    Publication date: August 26, 2010
    Applicant: ASTRAZENECA
    Inventors: Brian Aquila, Donald J. Cook, Craig Johnstone, Stephen Lee, Paul Lyne, David Alan Rudge, Melissa Vasbinder, Haixia Wang
  • PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
    Publication number: 20100152219
    Abstract: Compounds of formula (I): and their use in the inhibition of Trk activity are described.
    Type: Application
    Filed: February 25, 2010
    Publication date: June 17, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Michael Howard Block, John W. Lee, David Scott, Haixia Wang, Tao Wang, Dingwei Yu, Yongxin Han, John Anthony Josey, Bin Wang
  • FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS
    Publication number: 20100144744
    Abstract: Novel compounds are provided which are 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors. 1 1-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 1 1-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L are defined herein and Z is selected from the following bicyclic heteroaryl groups: (a), (b), (c), (d).
    Type: Application
    Filed: April 16, 2008
    Publication date: June 10, 2010
    Inventors: Jun Li, James J. Li, Stephen P. O'Connor, Haixia Wang, Lawrence J. Kennedy, Jeffrey A. Robl, Lawrence G. Hamann
  • Bicyclic compounds as modulators of androgen receptor function and method
    Patent number: 7732480
    Abstract: There are disclosed bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X and n are defined herein.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: June 8, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: James J. Li, Lawrence Hamann, Haixia Wang
  • Bicyclic compounds as modulators of androgen receptor function and method
    Patent number: 7696241
    Abstract: The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R1, R2, R5, X and n are defined herein.
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: April 13, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: James J. Li, Lawrence Hamann, Haixia Wang
  • Modulators of LXR
    Publication number: 20100056582
    Abstract: Compounds of the invention, such as compounds of formula (I): where n, m, A, B, R1, R2, R3, R4 and R5 are defined herein, are useful as modulators of the activity of liver X receptors. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Application
    Filed: December 17, 2008
    Publication date: March 4, 2010
    Applicant: X-CEPTOR THERAPEUTICS, INC.
    Inventors: Christopher D. Bayne, Alan T. Johnson, Shao-Po Lu, Raju Mohan, Michael C. Nyman, Edwin J. Schweiger, William C. Stevens, JR., Haixia Wang, Yinong Xie
  • HETEROARYL 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
    Publication number: 20090306084
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z??(I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L and Z are defined herein.
    Type: Application
    Filed: July 27, 2009
    Publication date: December 10, 2009
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang
  • Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 7579360
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L, R3, R3a, R3b and R4 are defined herein.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: August 25, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robl
  • TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
    Publication number: 20090203668
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R3, R3a, R3b and R4 are defined herein.
    Type: Application
    Filed: April 16, 2009
    Publication date: August 13, 2009
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robi
  • Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 7572807
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z??(I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L and Z are defined herein.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: August 11, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: James J. Li, Lawrence G. Hamann, Haixia Wang
  • METHOD FOR MAKING LACTOSE-REMOVING MILK
    Publication number: 20090123602
    Abstract: A method for removing lactose from milk comprising the steps of precipitation, ultrafiltration, re-dissolving, mixing, and restoration, with or without a step of degreasing prior to precipitation. The lactose-removed diary product can be liquid milk, milk powder, or combined with other products to make sugar-free or low-sugar healthy food. The milk used in the method can be milk from any mammals or milk obtained by dissolving milk powder in drinking water.
    Type: Application
    Filed: January 16, 2009
    Publication date: May 14, 2009
    Applicant: SHANGHAI SHANGLONG DAIRY CO.,LTD.
    Inventors: Yiqian YAN, Haixia Wang, Meiying Cao, Yimou Yan
  • TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
    Publication number: 20090093516
    Abstract: Novel compounds are provided which are 11 -beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.
    Type: Application
    Filed: September 9, 2008
    Publication date: April 9, 2009
    Inventors: Jun Li, Jeffrey A. Robl, James J. Li, Lawrence J. Kennedy, Haixia Wang, Jie Jack Li, Xinhua Qian, Rajendra P. Deshpande, Laxma R. Kolla, Reginald O. Cann, Chenkou Wei, Michael Galella